Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker.
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker.
复制标题
DOI：
10.3390/cancers14071728
复制
发表时间：
2022-03-29
期刊：
影响因子：
5.2
通讯作者：
Wang L
中科院分区：
文献类型：
--
作者：
Ionescu F;Zhang J;Wang L
液体活检（LB）包括对血液或尿液中循环肿瘤物质的分析，已成为治疗前列腺癌的有力工具。在局部肿瘤中，LB 可以区分低级别和高级别癌症，并可以指导决定进行或推迟组织活检。在晚期疾病状态下，除了前列腺特异性抗原等标准护理测试之外，LB 已被证明具有预后能力，并已在临床试验中用于评估反应。某些 LB 分析物可以预测对雄激素受体信号抑制剂的耐药性，但如何将其应用纳入日常临床决策仍不清楚。最后，对于少数患者，LB 可以识别具有重大治疗意义的基因组改变。 LB 的技术进步和创造性应用有望在不久的将来极大地改善前列腺癌患者的治疗。前列腺癌（PC）仍然是最常见的恶性肿瘤，也是男性癌症死亡的第二大常见原因。由于生物行为的高度可变以及在治疗压力下对可用药物产生耐药性，最佳管理通常不清楚。传统的手术活检，即使通过基因组研究增强，也可能无法为临床决策提供足够的指导，因为它们只能提供动态过程的快照。此外，手术活检重复进行很麻烦，而且常常存在风险。液体活检 (LB) 被定义为对红细胞（循环肿瘤细胞、细胞外囊泡）或分子（循环 DNA 或 RNA）肿瘤来源材料的分析。 LB 可以更准确地识别表征肿瘤转移潜力的临床相关改变，预测对特定治疗的反应或主动监测耐药性的出现。这些测试可以根据需要重复进行，并且可以检测对治疗的实时反应，同时尽量减少对患者的不便。在当前的综述中，我们考虑常见的临床场景来描述 PC 中可用的 LB 检测作为平台，以探索其在指导决策中的使用的现有证据，并讨论其在临床中采用的当前局限性。
Liquid biopsy (LB), encompassing the analysis of circulating tumor material in the blood or urine, has emerged as a powerful tool in the management of prostate cancer. In localized tumors, LB can distinguish between low- and high-grade cancers and can guide the decision to proceed with or defer tissue biopsy. In advanced disease states, LB has proven prognostic ability in addition to standard-of-care tests like the prostate-specific antigen and has been used in clinical trials to assess response. Certain LB analytes may predict resistance to androgen receptor signaling inhibitors, but how to incorporate their use into everyday clinical decision making remains unclear. Finally, for a minority of patients, LB can identify genomic alterations with significant therapeutic implications. Technological advances and creative uses of LB promise to greatly improve the management of prostate cancer patients in the near future. Prostate cancer (PC) remains the most common malignancy and the second most common cause of cancer death in men. As a result of highly variable biological behavior and development of resistance to available agents under therapeutic pressure, optimal management is often unclear. Traditional surgical biopsies, even when augmented by genomic studies, may fail to provide adequate guidance for clinical decisions as these can only provide a snapshot of a dynamic process. Additionally, surgical biopsies are cumbersome to perform repeatedly and often involve risk. Liquid biopsies (LB) are defined as the analysis of either corpuscular (circulating tumor cells, extracellular vesicles) or molecular (circulating DNA or RNA) tumor-derived material. LB could more precisely identify clinically relevant alterations that characterize the metastatic potential of tumors, predict response to specific treatments or actively monitor for the emergence of resistance. These tests can potentially be repeated as often as deemed necessary and can detect real-time response to treatment with minimal inconvenience to the patient. In the current review, we consider common clinical scenarios to describe available LB assays in PC as a platform to explore existing evidence for their use in guiding decision making and to discuss current limitations to their adoption in the clinic.
登录
查看更多内容
影响因子：
23.4
作者：
Borgmann, Hendrik;Lallous, Nada;Gleave, Martin E.
通讯作者：
Gleave, Martin E.
DOI：
10.1177/1010428319866369
发表时间：
2019-08-01
期刊：
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
影响因子：
--
作者：
Bronkhorst, Abel Jacobus;Ungerer, Vida;Holdenrieder, Stefan
通讯作者：
Holdenrieder, Stefan
原发性前列腺癌中预先存在的cast割前列腺癌样细胞可促进对激素疗法的抗性。
影响因子：
23.4
作者：
Cheng, Qing;Butler, William;Zhou, Yinglu;Zhang, Hong;Tang, Lu;Perkinson, Kathryn;Chen, Xufeng;Jiang, Xiaoyin ''Sara'';McCall, Shannon J.;Inman, Brant A.;Huang, Jiaoti
通讯作者：
Huang, Jiaoti
雄激素无关前列腺癌治疗的临床考虑。
影响因子：
4.8
作者：
Berchuck JE;Viscuse PV;Beltran H;Aparicio A
通讯作者：
Aparicio A
影响因子：
23.4
作者：
Casanova-Salas I;Athie A;Boutros PC;Del Re M;Miyamoto DT;Pienta KJ;Posadas EM;Sowalsky AG;Stenzl A;Wyatt AW;Mateo J
通讯作者：
Mateo J